Replies to post #322550 on Avid Bioservices Inc (CDMO)

[biopharm]

So what do you all think about BIOMARKERS now ?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134747702

CGI’s AntigenID™ identifies neoantigens and neoantigen signatures that accelerate immuno-oncology drug identification, predict patient-specific immune therapy response, and help create personalized immuno-vaccines – the immuno-oncology therapy and drug development market is expected to grow to nearly USD $200 Billion by 2021. [1]
http://www.cancergenetics.com/cancer-genetics-inc-a-leader-in-personalized-medicine-launches-antigenid-solidifying-cgis-position-as-a-precision-oncology-leader-in-the-fast-growing-rapidly/

CGI....tied in with MSK as well....so as we move forward, I hope the current BODs realize most if not all, new knowledge not previously known ....based upon PS Targeting Biomarker signatures may be allowing others to publicly announce various tests or file patents and PS Targeting IP rights may be leveraged further than anyone thinks.


ABOUT CANCER GENETICS
Cancer Genetics Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
http://www.cancergenetics.com/cancer-genetics-receives-new-york-state-approval-for-fda-approved-oncomine-dx-target-test-by-thermo-fisher-scientific/